InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,304.72
(
0.70%
)
US TECH 100
18,318.00
(
0.95%
)
Dow Jones
39,069.59
(
0.01%
)
Brent Oil
82.87
(
1.08%
)
Bitcoin
70,252.47
(
2.53%
)
Post# of 97237
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

bra1loga

Send PM Follow Ignore
Followers 385
Posts 8154
Boards Moderated 7
Alias Born 07/15/2007

bra1loga

Re: None

Thursday, 12/04/2014 11:38:03 AM

Thursday, December 04, 2014 11:38:03 AM

Post# of 97237
MSTX- MST-188 Significantly Decreased Thrombin Generation in Blood of Sickle Cell Anemia Patients

SAN DIEGO, Nov. 17, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (nyse mkt:MSTX), a clinical-stage biopharmaceutical company, today announced that it will be presenting data from an ex vivo study of MST-188 (vepoloxamer), its lead product candidate, at the 56th Annual Meeting of the American Society of Hematology (ASH) taking place December 6 – 9, 2014 in San Francisco, California.

Exchange Personmarks?

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up